Fisetin vs Apigenin: Senolytic vs CD38 Inhibitor (2026)

Fisetin vs apigenin: senolytic vs CD38 inhibitor — which matters more for longevity?

Fisetin and apigenin are both flavonoids, but they target different ageing pathways. Fisetin shows senolytic activity in selected preclinical models, while systemic senescent-cell clearance in humans remains unproven [1]. Apigenin inhibits CD38, an enzyme that degrades NAD and becomes more active with age [2].

Fisetin shows senolytic activity in selected preclinical models and has limited, heterogeneous human trial results. Apigenin inhibits CD38 in laboratory research, but the consequences of supplemental doses for human tissue NAD levels remain uncertain. No controlled human evidence establishes the safety or benefits of combining them. See our clinician's guide.

CD38 inhibition in experimental systems does not establish that an oral apigenin capsule raises human tissue NAD levels. Likewise, fisetin's cell-model senolytic activity does not establish a clinically effective oral regimen. For the distinct exposure questions see fisetin pharmacokinetics; for combination-related uncertainty see drug and supplement interactions and safety.

What are fisetin and apigenin, chemically?

Fisetin (3,3′,4′,7-tetrahydroxyflavone) is a flavonol — the same subclass as quercetin and kaempferol. It has been detected in strawberries and other foods, although reported concentrations vary with analytical methods and are not a reliable basis for fresh-fruit serving-dose calculations.

Apigenin (4′,5,7-trihydroxyflavone) is a flavone, a distinct flavonoid subclass. It's concentrated in parsley, chamomile flowers, celery, thyme, and oregano, and it's the compound most associated with chamomile tea's calming effect.

Both are polyphenolic antioxidants with anti-inflammatory activity. Both are present in ordinary healthy diets at low levels. Their specific longevity-relevant mechanisms are unrelated to each other.

How do the mechanisms differ — senolytic vs CD38 inhibition?

Fisetin: preclinical senolytic activity

Yousefzadeh and colleagues established fisetin's senolytic activity in selected experimental systems in 2018, with effects linked to several senescent-cell anti-apoptotic pathways [1]. See our dedicated senolytic article for the mechanism in detail.

Apigenin: CD38 inhibition and NAD preservation

CD38 is an enzyme that degrades NAD, the coenzyme central to mitochondrial energy production, sirtuin activity, and DNA repair. CD38 activity and expression increase with age, and this increase drives at least part of the well-documented age-related decline in tissue NAD levels [3]. Escande and colleagues identified apigenin (alongside quercetin) as a pharmacological CD38 inhibitor: in cell culture, apigenin raised intracellular NAD and reduced protein acetylation, and in obese mice, apigenin administration increased NAD levels and improved several markers of glucose and lipid metabolism [2].

This makes apigenin conceptually different from NAD precursor supplements such as NMN or NR: instead of adding NAD substrate, it slows the enzymatic breakdown of the NAD already present. The two strategies are mechanistically complementary, at least in theory — this combination hasn't been tested directly in a human trial.

Why the mechanisms don't compete

Fisetin removes senescent cells that would otherwise keep producing inflammatory SASP factors. Apigenin, if the mouse-model mechanism holds in humans, preserves NAD levels in the cells that remain. These are different problems addressed by different tools, which is the basis for the common practice of stacking them.

What does the human evidence show?

Apigenin's human trials

Apigenin's human trial base is thin. Most human data comes from chamomile, a natural source of apigenin, studied mainly for anxiety and sleep rather than for NAD preservation or cardiometabolic endpoints specifically. Two narrative reviews of apigenin's broader biological effects — one summarising in vivo and human evidence across several disease areas [4], and one focused on apigenin's antioxidant and metabolic functionality [5] — both describe the human evidence as considerably behind the preclinical mechanistic case. Neither review, nor any dedicated trial we could verify, reports a completed human study measuring whether oral apigenin supplementation raises tissue NAD levels or shifts cardiometabolic biomarkers in people. That specific chain — apigenin dose, to CD38 inhibition, to measurable NAD change, to a clinical benefit — remains unproven in humans.

Fisetin's human trials

Fisetin has several registered trials and some completed human results, though its human evidence remains limited and heterogeneous. Available findings do not establish systemic senolytic benefit or longevity efficacy. AFFIRM remains unreported [6]; other completed trials should not be overlooked when comparing clinical evidence.

How do the typical doses compare?

Aspect	Fisetin	Apigenin
Mechanism	Candidate senolytic (preclinical clearance; human systemic clearance unproven)	CD38 inhibitor (preserves NAD)
Typical daily dose	100–500 mg (continuous) or 20 mg/kg pulsed	50–300 mg daily, continuous
Dietary sources	Strawberries, apples, persimmons	Parsley, chamomile, celery, thyme, oregano
Bioavailability	Poor absorption, low plasma peaks	Poor — rapid glucuronidation and sulphation
Peer-reviewed human RCT with a functional endpoint	Limited human findings; systemic senolytic benefit unproven	None yet published specific to CD38/NAD outcomes

How do their evidence bases differ?

Apigenin's CD38-related effects and NAD findings come primarily from laboratory and animal research, without adequate human trials showing NAD-related clinical benefits at supplement doses. Fisetin's senolytic activity is demonstrated in selected experimental models, while clinical benefits in humans remain uncertain. These mechanisms generate distinct research hypotheses, not an evidence-based recommendation to combine apigenin with fisetin, NMN or NR.

Is it safe to combine fisetin and apigenin?

The mechanisms are different enough to make combination hypotheses scientifically interesting, but no controlled human trial has established that combining these compounds improves efficacy or safety. Absence of a documented interaction should not be treated as proof of compatibility at supplemental doses.

Further reading: the spermidine comparison, which concerns a different pathway. Different mechanistic targets do not establish clinical synergy.

What we still don't know

Whether apigenin at supplement doses meaningfully raises tissue NAD levels in humans — the mouse data are suggestive, but no human trial has tested this directly.

Whether AFFIRM and other randomized fisetin trials will provide reproducible evidence of human senescence-target engagement beyond the limited markers measured in existing clinical research.

Whether combining fisetin and apigenin produces any additive human benefit — not tested in any trial.

Whether the CD38-inhibition strategy proves clinically meaningful on its own, or mainly as a complement to direct NAD precursor supplementation — this hasn't been resolved even at the mechanistic level.

Bottom line

Fisetin has senolytic activity in selected preclinical systems; apigenin shows CD38 inhibition in laboratory experiments. Fisetin has a limited, heterogeneous human trial record, and the proposed NAD-preserving effects of apigenin have not been validated as a clinical longevity intervention. Neither has proven human lifespan benefits, and no adequate controlled trial establishes the safety or benefit of combining concentrated supplements. See our clinician's guide.